Senti Biosciences Holdings, Inc.

Amparo Investor Rights is investigating whether the proxy materials filed in connection with Senti’s proposed merger omit information shareholders need to make an informed decision on the deal — and whether shareholders may be entitled to additional disclosures, or other relief, before the vote.

Time-sensitive — act before the vote

Estimated 18 days to the shareholder vote

Merger-objection claims must be raised before the transaction closes. There is no PSLRA lead-plaintiff process; the window to act is generally before the shareholder vote or the closing of the deal.

Hero renders three ACF fields only: exchange+ticker (pill), the primary taxonomy term (category tag), and headline_summary (the curated lede — never the post excerpt or the 8-K meta-description). Show the deadline banner only when deadline_date/vote_date is set and future; otherwise hide it. H1 = company name only (the live page appends "— Shareholder Investigation"; removed here).

Held shares of Senti?

Tell us about your position. No obligation. Confidential. You’ll review and sign the Retainer Agreement below — we handle these matters on contingency.

Prefer to talk first? Call (888) 577-7817.

What we're investigating.

Amparo Investor Rights is reviewing whether Senti’s board of directors complied with its fiduciary duties in agreeing to the proposed merger, and whether the proxy statement and related solicitation materials filed with the SEC omit information material to shareholders’ decision on the deal. Our review focuses on whether the proxy adequately discloses:

  • the financial projections management relied upon, and the specific inputs underlying the financial advisor’s valuation analyses — including the discount-rate (weighted average cost of capital) and terminal-growth assumptions behind any discounted-cash-flow analysis;
  • the nature, extent, and fees of any prior or concurrent engagements between the buyer (or its principals and affiliates) and the financial advisor who rendered the fairness opinion, so shareholders can assess that opinion’s independence; and
  • where the transaction involves an affiliated counterparty, the composition and independence of any special committee, the procedural protections adopted, and the change-in-control compensation arrangements for named executive officers.

If you hold shares of Senti Biosciences Holdings, Inc. and the transaction has not yet closed, you may be entitled to seek additional disclosures or other relief. The window to act is generally before the shareholder vote or the closing of the deal.

If you held shares.

You may be eligible to participate if you:

  • held shares of SNTI before the transaction was announced, or hold shares now; and
  • are reviewing the deal before the shareholder vote or the closing.

There is no cost to participate, and joining the investigation does not create an attorney-client relationship until a written retainer is signed. Investors in all 50 states and internationally are eligible.

How merger-objection claims work.

These claims seek to protect shareholders’ right to a fully informed vote. Relief commonly takes the form of corrective disclosures before the vote, improved deal terms, or, in appropriate cases, an order delaying the vote until shareholders receive complete information. Unlike a securities class action, a merger-objection matter is time-sensitive and centered on the period before the transaction closes — there is no PSLRA lead-plaintiff process.

Shareholders are encouraged to contact us before the shareholder vote or the closing of the transaction.

How representation works.

  • Contingency fee. No out-of-pocket cost to clients. The firm advances expenses and recovers them only from any recovery obtained.
  • Federal-court venue. Merger-disclosure claims proceed in federal court under Section 14(a) of the Securities Exchange Act and SEC Rule 14a-9.
  • Direct attorney communication. You will speak with the attorney handling your matter, not layers of intake staff.
  • National practice. Investors in all 50 states and internationally are eligible.

This body is curated case prose bound to ACF rich-text fields (what_we_investigate, if_you_held, etc.). It must not render the raw press release, the GlobeNewswire wire copy, or the internal "Review Flags for Bob Amirian" table — all of which are currently exposed on the live page and must stay attorney-only / unpublished. Replace the "Read the SEC Form 8-K announcement" link block with a curated body.

Investigation facts
Issuer

Senti Biosciences Holdings, Inc.

Ticker

NASDAQ: SNTI

Type

M&A Disclosure

Theory

§14(a) / Rule 14a-9

Status

Investigating

Render a fact row only when its ACF field is populated. The live page prints empty "Class period / Vote / Court" rows and raises ACF "value must be string, but is type of NULL" warnings — suppress empty rows with a conditional, and never echo PHP warnings to the page.

Releases on this matter
May 20, 2026

Investigation announced

Pending

Proxy-specific findings (on EDGAR filing)

Loop published releases tagged to this issuer; hide the box if none are published.

Held shares of Senti? Tell us.

Merger-objection claims must be raised before the transaction closes, so timing matters. The conversation is free, confidential, and creates no obligation.

Attorney Advertising. Prior results do not guarantee a similar outcome.

Related investigations

LiveRamp Holdings, Inc.

Investigating whether LiveRamp’s merger proxy adequately discloses the financial analyses underlying the board’s recommendation.

Emerald Holding, Inc.

Reviewing the proxy disclosures around Emerald’s proposed transaction for omissions material to a shareholder vote.

Mister Car Wash, Inc.

Examining the disclosures in Mister Car Wash’s announced merger and whether shareholders received the information needed for an informed vote.

Related strip = up to 3 other Investigation entries sharing this one’s primary category, excluding the current post. Hide the whole section if fewer than 1 related entry exists.